| . | Value . |
|---|---|
| Biologic/small molecule, n (%) | 227 (63.8) |
| Infliximab | 80 (35.2%) |
| Adalimumab | 60 (26.4%) |
| Ustekinumab | 49 (21.6%) |
| Vedolizumab | 33 (14.5%) |
| Tofacitinib | 3 (1.3%) |
| Combination biologics | 2 (1.0%) |
| Immunomodulator monotherapy, n (%) | 26 (7%) |
| Thiopurine | 23 (88.5%) |
| Methotrexate | 3 (11.5%) |
| Combination biologic and immunomodulator, n (%) | 59 (16.7%) |
| Corticosteroids (prednisone and budesonide), n (%) | 36 (10.1%) |
| Mesalamine, n (%) | 76 (21.3%) |
| . | Value . |
|---|---|
| Biologic/small molecule, n (%) | 227 (63.8) |
| Infliximab | 80 (35.2%) |
| Adalimumab | 60 (26.4%) |
| Ustekinumab | 49 (21.6%) |
| Vedolizumab | 33 (14.5%) |
| Tofacitinib | 3 (1.3%) |
| Combination biologics | 2 (1.0%) |
| Immunomodulator monotherapy, n (%) | 26 (7%) |
| Thiopurine | 23 (88.5%) |
| Methotrexate | 3 (11.5%) |
| Combination biologic and immunomodulator, n (%) | 59 (16.7%) |
| Corticosteroids (prednisone and budesonide), n (%) | 36 (10.1%) |
| Mesalamine, n (%) | 76 (21.3%) |
| . | Value . |
|---|---|
| Biologic/small molecule, n (%) | 227 (63.8) |
| Infliximab | 80 (35.2%) |
| Adalimumab | 60 (26.4%) |
| Ustekinumab | 49 (21.6%) |
| Vedolizumab | 33 (14.5%) |
| Tofacitinib | 3 (1.3%) |
| Combination biologics | 2 (1.0%) |
| Immunomodulator monotherapy, n (%) | 26 (7%) |
| Thiopurine | 23 (88.5%) |
| Methotrexate | 3 (11.5%) |
| Combination biologic and immunomodulator, n (%) | 59 (16.7%) |
| Corticosteroids (prednisone and budesonide), n (%) | 36 (10.1%) |
| Mesalamine, n (%) | 76 (21.3%) |
| . | Value . |
|---|---|
| Biologic/small molecule, n (%) | 227 (63.8) |
| Infliximab | 80 (35.2%) |
| Adalimumab | 60 (26.4%) |
| Ustekinumab | 49 (21.6%) |
| Vedolizumab | 33 (14.5%) |
| Tofacitinib | 3 (1.3%) |
| Combination biologics | 2 (1.0%) |
| Immunomodulator monotherapy, n (%) | 26 (7%) |
| Thiopurine | 23 (88.5%) |
| Methotrexate | 3 (11.5%) |
| Combination biologic and immunomodulator, n (%) | 59 (16.7%) |
| Corticosteroids (prednisone and budesonide), n (%) | 36 (10.1%) |
| Mesalamine, n (%) | 76 (21.3%) |
This PDF is available to Subscribers Only
View Article Abstract & Purchase OptionsFor full access to this pdf, sign in to an existing account, or purchase an annual subscription.
